Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789320 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
A Phase 1 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01789320: Completed Phase 1 study, sponsored by Clearside Biomedical.
NCT01789320 is a Phase 1 study that has completed, run by Clearside Biomedical. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01789320, a Phase 1 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
Primary Outcome
Intraocular pressure is the fluid pressure inside the eye. Intraocular pressure change from baseline at week 8 was measured by Goldmann applanation tonometry. Tonometry is the method eye care professionals use to determine this pressure. Intraocular pressure is typically measured in millimeters of mercury. A higher pressure inside the eye can be a risk factor for developing glaucoma or glaucoma progression leading to optic nerve damage. A negative change indicates a reduction in intraocular pres
Interventions
- DRUG triamcinolone acetonide (Triesence®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT01789320 record still lists
NCT01789320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which triamcinolone acetonide (Triesence®) is the first listed.
NCT01789320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01789320 about?
NCT01789320 is a clinical study titled "Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis". This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
What is the current status of trial NCT01789320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01789320?
The interventions under investigation include: triamcinolone acetonide (Triesence®) (DRUG).
Who is sponsoring clinical trial NCT01789320?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01789320's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia